{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:09:53Z","timestamp":1790698193293,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Diabetes mellitus bezeichnet eine Gruppe von heterogenen Erkrankungen, deren gemeinsamer Befund die Erh\u00f6hung der Blutglukosekonzentration ist. Die gegenw\u00e4rtige Klassifikation des Diabetes mellitus wird dargestellt, und die wesentlichen Merkmale von Typ\u00a01, Typ\u00a02 und der h\u00e4ufigsten Form des monogenetischen Diabetes (MODY) werden gegen\u00fcbergestellt. Dar\u00fcber hinaus werden die Kriterien f\u00fcr die korrekte biochemische Diagnose unter N\u00fcchternbedingungen und im oralen Glukosetoleranztest sowie die Anwendung von H\u00e4moglobin\u00a0A\n                    <jats:sub>1c<\/jats:sub>\n                    (HbA\n                    <jats:sub>1c<\/jats:sub>\n                    ) zusammengefasst. Die zunehmende Pr\u00e4valenz des Diabetes erfordert zudem gezieltes Screening zur Erkennung von Diabetes und Pr\u00e4diabetes in Risikogruppen. Dies bildet die Grundlage f\u00fcr die fr\u00fchzeitige Einleitung von Lebensstil\u00e4nderung und medikament\u00f6sen Ma\u00dfnahmen zur Pr\u00e4vention der Manifestation des Diabetes in Risikogruppen und Verz\u00f6gerung der Diabetesprogression.\n                  <\/jats:p>","DOI":"10.1007\/s00508-025-02627-2","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:41Z","timestamp":1779315401000},"page":"76-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes mellitus\u2014Definition, Klassifikation, Diagnose, Screening und Pr\u00e4vention (Update 2026)","Diabetes mellitus\u2014definition, classification, diagnosis, screening and prevention (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"J\u00fcrgen","family":"Harreiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2627_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas -11th\u00a0edition 2025 11th https:\/\/diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/04\/IDF_Atlas_11th_Edition_2025.pdf."},{"key":"2627_CR2","unstructured":"Federation ID. IDF Diabetes Atlas 10th\u00a0edition. 2021. www.diabetesatlas.org.."},{"key":"2627_CR3","volume-title":"\u00d6sterreichischer Diabetesbericht","year":"2017","unstructured":"Schmutterer\u00a0IDJ, Griebler\u00a0R, Hrsg. \u00d6sterreichischer Diabetesbericht. Bd. 2017. Wien: Bundesministerium f\u00fcr Gesundheit und Frauen; 2017."},{"issue":"3","key":"2627_CR4","doi-asserted-by":"publisher","first-page":"e13207","DOI":"10.1111\/eci.13207","volume":"50","author":"MK Breyer","year":"2020","unstructured":"Breyer\u00a0MK, Ofenheimer\u00a0A, Altziebler\u00a0J, Hartl\u00a0S, Burghuber\u00a0OC, Studnicka\u00a0M, et\u00a0al. Marked differences in prediabetes- and diabetes-associated comorbidities between men and women-Epidemiological results from a\u00a0general population-based cohort aged 6\u201380\u00a0years-The LEAD (Lung, hEart, sociAl, boDy) study. Eur J Clin Invest. 2020;50(3):e13207.","journal-title":"Eur J Clin Invest"},{"key":"2627_CR5","doi-asserted-by":"publisher","first-page":"i5953","DOI":"10.1136\/bmj.i5953","volume":"355","author":"Y Huang","year":"2016","unstructured":"Huang\u00a0Y, Cai\u00a0X, Mai\u00a0W, Li\u00a0M, Hu\u00a0Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.","journal-title":"BMJ"},{"issue":"1","key":"2627_CR6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1):S27\u2013S49.","journal-title":"Diabetes Care"},{"issue":"3","key":"2627_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1055\/a-2166-6643","volume":"132","author":"S Pleus","year":"2024","unstructured":"Pleus\u00a0S, Tytko\u00a0A, Landgraf\u00a0R, Heinemann\u00a0L, Werner\u00a0C, Muller-Wieland\u00a0D, et\u00a0al. Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023. Exp Clin Endocrinol Diabetes. 2024;132(3):112\u201324.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"2627_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"Haller\u00a0MJ, Bell\u00a0KJ, Besser\u00a0REJ, Casteels\u00a0K, Couper\u00a0JJ, Craig\u00a0ME, et\u00a0al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type\u00a01 Diabetes. Horm Res Paediatr. 2024;97(6):529\u201345.","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"2627_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist\u00a0E, Storm\u00a0P, Karajamaki\u00a0A, Martinell\u00a0M, Dorkhan\u00a0M, Carlsson\u00a0A, et\u00a0al. Novel subgroups of adult-onset diabetes and their association with outcomes: a\u00a0data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2627_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia\u00a0OP, Strassburger\u00a0K, Strom\u00a0A, Bonhof\u00a0GJ, Karusheva\u00a0Y, Antoniou\u00a0S, et\u00a0al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a\u00a05-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2627_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41588-021-00948-2","volume":"53","author":"MD Aly","year":"2021","unstructured":"Aly\u00a0MD, Dwivedi\u00a0OP, Prasad\u00a0RB, Karajamaki\u00a0A, Hjort\u00a0R, Thangam\u00a0M, et\u00a0al. Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes. Nat Genet. 2021;53(11):1534\u201342.","journal-title":"Nat Genet"},{"issue":"8003","key":"2627_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","volume":"627","author":"K Suzuki","year":"2024","unstructured":"Suzuki\u00a0K, Hatzikotoulas\u00a0K, Southam\u00a0L, Taylor\u00a0HJ, Yin\u00a0X, Lorenz\u00a0KM, et\u00a0al. Genetic drivers of heterogeneity in type\u00a02 diabetes pathophysiology. Nature. 2024;627(8003):347\u201357.","journal-title":"Nature"},{"issue":"1","key":"2627_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00508-023-02181-9","volume":"135","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer\u00a0A, Winhofer\u00a0Y, Kiss\u00a0H, Falcone\u00a0V, Berger\u00a0A, Lechleitner\u00a0M, et\u00a0al. Gestational diabetes mellitus (Update 2023). Wien Klin Wochenschr. 2023;135(1):115\u201328.","journal-title":"Wien Klin Wochenschr"},{"issue":"23","key":"2627_CR14","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2214956","volume":"388","author":"D Simmons","year":"2023","unstructured":"Simmons\u00a0D, Immanuel\u00a0J, Hague\u00a0WM, Teede\u00a0H, Nolan\u00a0CJ, Peek\u00a0MJ, et\u00a0al. Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. N\u00a0Engl J Med. 2023;388(23):2132\u201344.","journal-title":"N Engl J Med"},{"key":"2627_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/DMSO.S39093","volume":"6","author":"B Kowall","year":"2013","unstructured":"Kowall\u00a0B, Rathmann\u00a0W. HbA1c for diagnosis of type\u00a02 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5\u202f% cutoff perform? Diabetes Metab Syndr Obes. 2013;6:477\u201391.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"27","key":"2627_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/pedi.12773","volume":"19","author":"EJ Mayer-Davis","year":"2018","unstructured":"Mayer-Davis\u00a0EJ, Kahkoska\u00a0AR, Jefferies\u00a0C, Dabelea\u00a0D, Balde\u00a0N, Gong\u00a0CX, et\u00a0al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19(27):7\u201319.","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"2627_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.diabres.2011.06.025","volume":"93","author":"S Colagiuri","year":"2011","unstructured":"Colagiuri\u00a0S. Glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus\u2014practical implications. Diabetes Res Clin Pract. 2011;93(3):312\u20133.","journal-title":"Diabetes Res Clin Pract"},{"key":"2627_CR18","unstructured":"H\u00fcbl W, Haushofer A, Weitgasser R. Gemeinsame Empfehlungen der \u00d6GLMKC und der \u00d6DG zur Referenzierung der HBA1C Bestimmung nach dem IFCC Standard. 2011. www.oeglmkc.at\/down\/HbA1c_Empfehlung2011.pdf."},{"issue":"10","key":"2627_CR19","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.2337\/dci23-0036","volume":"46","author":"DB Sacks","year":"2023","unstructured":"Sacks\u00a0DB, Arnold\u00a0M, Bakris\u00a0GL, Bruns\u00a0DE, Horvath\u00a0AR, Lernmark\u00a0A, et\u00a0al. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023;46(10):e151\u2013e99.","journal-title":"Diabetes Care"},{"issue":"11","key":"2627_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","volume":"67","author":"European Association for the Study of the L","year":"2024","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67(11):2375\u201392.","journal-title":"Diabetologia"},{"issue":"6","key":"2627_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer\u00a0A, Leutner\u00a0M, Harreiter\u00a0J. Sex differences in type\u00a02 diabetes. Diabetologia. 2023;66(6):986\u20131002.","journal-title":"Diabetologia"},{"issue":"6","key":"2627_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10654-010-9452-6","volume":"25","author":"B Kowall","year":"2010","unstructured":"Kowall\u00a0B, Rathmann\u00a0W, Strassburger\u00a0K, Heier\u00a0M, Holle\u00a0R, Thorand\u00a0B, et\u00a0al. Association of passive and active smoking with incident type\u00a02 diabetes in the elderly population: the KORA S4\/F5 cohort study. Eur J Epidemiol. 2010;25(6):393\u2013402.","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"2627_CR23","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","volume":"177","author":"JS Haw","year":"2017","unstructured":"Haw\u00a0JS, Galaviz\u00a0KI, Straus\u00a0AN, Kowalski\u00a0AJ, Magee\u00a0MJ, Weber\u00a0MB, et\u00a0al. Long-term Sustainability of Diabetes Prevention Approaches: A\u00a0Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2017;177(12):1808\u201317.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2627_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00125-014-3439-x","volume":"58","author":"A Glechner","year":"2015","unstructured":"Glechner\u00a0A, Harreiter\u00a0J, Gartlehner\u00a0G, Rohleder\u00a0S, Kautzky\u00a0A, Tuomilehto\u00a0J, et\u00a0al. Sex-specific differences in diabetes prevention: a\u00a0systematic review and meta-analysis. Diabetologia. 2015;58(2):242\u201354.","journal-title":"Diabetologia"},{"issue":"1","key":"2627_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12916-017-0984-4","volume":"16","author":"S Roberts","year":"2018","unstructured":"Roberts\u00a0S, Craig\u00a0D, Adler\u00a0A, McPherson\u00a0K, Greenhalgh\u00a0T. Economic evaluation of type\u00a02 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia. BMC Med. 2018;16(1):16.","journal-title":"BMC Med"},{"issue":"6","key":"2627_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","volume":"7","author":"Q Gong","year":"2019","unstructured":"Gong\u00a0Q, Zhang\u00a0P, Wang\u00a0J, Ma\u00a0J, An\u00a0Y, Chen\u00a0Y, et\u00a0al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2627_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00125-021-05401-x","volume":"64","author":"Y Chen","year":"2021","unstructured":"Chen\u00a0Y, Zhang\u00a0P, Wang\u00a0J, Gong\u00a0Q, An\u00a0Y, Qian\u00a0X, et\u00a0al. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a\u00a0secondary analysis of the 30\u00a0year Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2021;64(6):1279\u201387.","journal-title":"Diabetologia"},{"issue":"9","key":"2627_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2337\/dc19-0244","volume":"42","author":"L Perreault","year":"2019","unstructured":"Perreault\u00a0L, Pan\u00a0Q, Schroeder\u00a0EB, Kalyani\u00a0RR, Bray\u00a0GA, Dagogo-Jack\u00a0S, et\u00a0al. Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care. 2019;42(9):1809\u201315.","journal-title":"Diabetes Care"},{"issue":"12","key":"2627_CR29","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.2337\/dc21-1046","volume":"44","author":"CG Lee","year":"2021","unstructured":"Lee\u00a0CG, Heckman-Stoddard\u00a0B, Dabelea\u00a0D, Gadde\u00a0KM, Ehrmann\u00a0D, Ford\u00a0L, et\u00a0al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021;44(12):2775\u201382.","journal-title":"Diabetes Care"},{"issue":"1","key":"2627_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00508-019-1455-z","volume":"131","author":"H Brath","year":"2019","unstructured":"Brath\u00a0H, Kaser\u00a0S, Tatschl\u00a0C, Fasching\u00a0P. Smoking, alcohol and diabetes (Update 2019). Wien Klin Wochenschr. 2019;131(1):67\u201370.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2627_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/sleep\/34.3.371","volume":"34","author":"SM Schmid","year":"2011","unstructured":"Schmid\u00a0SM, Hallschmid\u00a0M, Jauch-Chara\u00a0K, Wilms\u00a0B, Lehnert\u00a0H, Born\u00a0J, et\u00a0al. Disturbed glucoregulatory response to food intake after moderate sleep restriction. Sleep. 2011;34(3):371\u20137.","journal-title":"Sleep"},{"issue":"3","key":"2627_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/SLA.0000000000000863","volume":"261","author":"S Panunzi","year":"2015","unstructured":"Panunzi\u00a0S, De Gaetano\u00a0A, Carnicelli\u00a0A, Mingrone\u00a0G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A\u00a0meta-analysis. Ann Surg. 2015;261(3):459\u201367.","journal-title":"Ann Surg"},{"key":"2627_CR33","doi-asserted-by":"crossref","unstructured":"van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, et\u00a0al. Bariatric surgery and cardiovascular disease: a\u00a0systematic review and meta-analysis. Eur Heart\u00a0J. 2022;.","DOI":"10.1093\/eurheartj\/ehac071"},{"issue":"6","key":"2627_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler\u00a0WC, Barrett-Connor\u00a0E, Fowler\u00a0SE, Hamman\u00a0RF, Lachin\u00a0JM, Walker\u00a0EA, et\u00a0al. Reduction in the incidence of type\u00a02 diabetes with lifestyle intervention or metformin. N\u00a0Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"18","key":"2627_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto\u00a0J, Lindstrom\u00a0J, Eriksson\u00a0JG, Valle\u00a0TT, Hamalainen\u00a0H, Ilanne-Parikka\u00a0P, et\u00a0al. Prevention of type\u00a02 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N\u00a0Engl J Med. 2001;344(18):1343\u201350.","journal-title":"N Engl J Med"},{"issue":"9626","key":"2627_CR36","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","volume":"371","author":"G Li","year":"2008","unstructured":"Li\u00a0G, Zhang\u00a0P, Wang\u00a0J, Gregg\u00a0EW, Yang\u00a0W, Gong\u00a0Q, et\u00a0al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a\u00a020-year follow-up study. Lancet. 2008;371(9626):1783\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2627_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","volume":"49","author":"A Ramachandran","year":"2006","unstructured":"Ramachandran\u00a0A, Snehalatha\u00a0C, Mary\u00a0S, Mukesh\u00a0B, Bhaskar\u00a0AD, Vijay\u00a0V, et\u00a0al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type\u00a02 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289\u201397.","journal-title":"Diabetologia"},{"issue":"5","key":"2627_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1464-5491.2008.02417.x","volume":"25","author":"C Roumen","year":"2008","unstructured":"Roumen\u00a0C, Corpeleijn\u00a0E, Feskens\u00a0EJ, Mensink\u00a0M, Saris\u00a0WH, Blaak\u00a0EE. Impact of 3\u2011year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med. 2008;25(5):597\u2013605.","journal-title":"Diabet Med"},{"key":"2627_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/1471-2458-9-342","volume":"9","author":"L Penn","year":"2009","unstructured":"Penn\u00a0L, White\u00a0M, Oldroyd\u00a0J, Walker\u00a0M, Alberti\u00a0KG, Mathers\u00a0JC. Prevention of type\u00a02 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Heal. 2009;9:342.","journal-title":"BMC Public Heal"},{"issue":"15","key":"2627_CR40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/archinternmed.2011.275","volume":"171","author":"T Saito","year":"2011","unstructured":"Saito\u00a0T, Watanabe\u00a0M, Nishida\u00a0J, Izumi\u00a0T, Omura\u00a0M, Takagi\u00a0T, et\u00a0al. Lifestyle modification and prevention of type\u00a02 diabetes in overweight Japanese with impaired fasting glucose levels: a\u00a0randomized controlled trial. Arch Intern Med. 2011;171(15):1352\u201360.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2627_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2458-11-40","volume":"11","author":"N Sakane","year":"2011","unstructured":"Sakane\u00a0N, Sato\u00a0J, Tsushita\u00a0K, Tsujii\u00a0S, Kotani\u00a0K, Tsuzaki\u00a0K, et\u00a0al. Prevention of type\u00a02 diabetes in a\u00a0primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011;11(1):40.","journal-title":"BMC Public Health"},{"issue":"1","key":"2627_CR42","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.2337\/dc25-S003","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1):S50\u2013S8.","journal-title":"Diabetes Care"},{"issue":"3","key":"2627_CR43","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.2196\/jmir.4709","volume":"19","author":"RR Bian","year":"2017","unstructured":"Bian\u00a0RR, Piatt\u00a0GA, Sen\u00a0A, Plegue\u00a0MA, De Michele\u00a0ML, Hafez\u00a0D, et\u00a0al. The Effect of Technology-Mediated Diabetes Prevention Interventions on Weight: A\u00a0Meta-Analysis. J\u00a0Med Internet Res. 2017;19(3):e76.","journal-title":"J Med Internet Res"},{"issue":"5","key":"2627_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dci19-0014","volume":"42","author":"AB Evert","year":"2019","unstructured":"Evert\u00a0AB, Dennison\u00a0M, Gardner\u00a0CD, Garvey\u00a0WT, Lau\u00a0KHK, MacLeod\u00a0J, et\u00a0al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A\u00a0Consensus Report. Diabetes Care. 2019;42(5):731\u201354.","journal-title":"Diabetes Care"},{"issue":"6","key":"2627_CR45","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/advances\/nmab063","volume":"12","author":"MA Jardine","year":"2021","unstructured":"Jardine\u00a0MA, Kahleova\u00a0H, Levin\u00a0SM, Ali\u00a0Z, Trapp\u00a0CB, Barnard\u00a0ND. Perspective: Plant-Based Eating Pattern for Type\u00a02 Diabetes Prevention and Treatment: Efficacy, Mechanisms, and Practical Considerations. Adv Nutr. 2021;12(6):2045\u201355.","journal-title":"Adv Nutr"},{"issue":"10","key":"2627_CR46","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamainternmed.2019.2195","volume":"179","author":"F Qian","year":"2019","unstructured":"Qian\u00a0F, Liu\u00a0G, Hu\u00a0FB, Bhupathiraju\u00a0SN, Sun\u00a0Q. Association Between Plant-Based Dietary Patterns and Risk of Type\u00a02 Diabetes: A\u00a0Systematic Review and Meta-analysis. JAMA Intern Med. 2019;179(10):1335\u201344.","journal-title":"JAMA Intern Med"},{"key":"2627_CR47","doi-asserted-by":"crossref","unstructured":"Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Mediterranean dietary pattern and the risk of type\u00a02 diabetes: a\u00a0systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Nutr. 2022;.","DOI":"10.1007\/s00394-021-02761-3"},{"key":"2627_CR48","doi-asserted-by":"crossref","unstructured":"Lee Y, Park K. Adherence to a\u00a0Vegetarian Diet and Diabetes Risk: A\u00a0Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2017;9(6).","DOI":"10.3390\/nu9060603"},{"issue":"2","key":"2627_CR49","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1210\/clinem\/dgaf040","volume":"110","author":"EL Lundgrin","year":"2025","unstructured":"Lundgrin\u00a0EL, Hatipoglu\u00a0B. Trending Modalities in Type\u00a02 Diabetes Prevention. J\u00a0Clin Endocrinol Metab. 2025;110(2):S187\u2013S92.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2627_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00508-022-02122-y","volume":"135","author":"J Harreiter","year":"2023","unstructured":"Harreiter\u00a0J, Roden\u00a0M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023). Wien Klin Wochenschr. 2023;135(1):7\u201317.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"2627_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13098-024-01371-3","volume":"16","author":"HM Salamah","year":"2024","unstructured":"Salamah\u00a0HM, Marey\u00a0A, Abugdida\u00a0M, Abualkhair\u00a0KA, Elshenawy\u00a0S, Elhassan\u00a0WAF, et\u00a0al. Efficacy and safety of glucagon-like peptide\u20111 receptor agonists on prediabetes: a\u00a0systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16(1):129.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2627_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/clinem\/dgac591","volume":"108","author":"Y Mori","year":"2022","unstructured":"Mori\u00a0Y, Duru\u00a0OK, Tuttle\u00a0KR, Fukuma\u00a0S, Taura\u00a0D, Harada\u00a0N, et\u00a0al. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type\u00a02 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. J\u00a0Clin Endocrinol Metab. 2022;108(1):221\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9716","key":"2627_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar\u00a0N, Preiss\u00a0D, Murray\u00a0HM, Welsh\u00a0P, Buckley\u00a0BM, de Craen\u00a0AJ, et\u00a0al. Statins and risk of incident diabetes: a\u00a0collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"issue":"5","key":"2627_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","volume":"46","author":"H Abuissa","year":"2005","unstructured":"Abuissa\u00a0H, Jones\u00a0PG, Marso\u00a0SP, O\u2019Keefe\u00a0JH Jr.. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type\u00a02 diabetes: a\u00a0meta-analysis of randomized clinical trials. J\u00a0Am Coll Cardiol. 2005;46(5):821\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2627_CR55","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-025-58721-6","volume":"16","author":"DK Tobias","year":"2025","unstructured":"Tobias\u00a0DK, Pradhan\u00a0AD, Duran\u00a0EK, Li\u00a0C, Song\u00a0Y, Buring\u00a0JE, et\u00a0al. Vitamin\u00a0D supplementation vs. placebo and incident type\u00a02 diabetes in an ancillary study of the randomized Vitamin\u00a0D and Omega\u20113 Trial. Nat Commun. 2025;16(1):3332.","journal-title":"Nat Commun"},{"issue":"3","key":"2627_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.7326\/M22-3018","volume":"176","author":"AG Pittas","year":"2023","unstructured":"Pittas\u00a0AG, Kawahara\u00a0T, Jorde\u00a0R, Dawson-Hughes\u00a0B, Vickery\u00a0EM, Angellotti\u00a0E, et\u00a0al. Vitamin\u00a0D and Risk for Type\u00a02 Diabetes in People With Prediabetes : A\u00a0Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Ann Intern Med. 2023;176(3):355\u201363.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2627_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00125-024-06092-w","volume":"67","author":"H Hyoty","year":"2024","unstructured":"Hyoty\u00a0H, Kaariainen\u00a0S, Laiho\u00a0JE, Comer\u00a0GM, Tian\u00a0W, Harkonen\u00a0T, et\u00a0al. Safety, tolerability and immunogenicity of PRV-101, a\u00a0multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type\u00a01 diabetes: a\u00a0double-blind randomised placebo-controlled Phase\u00a0I trial. Diabetologia. 2024;67(5):811\u201321.","journal-title":"Diabetologia"},{"key":"2627_CR58","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","volume":"375","author":"J Chen","year":"2024","unstructured":"Chen\u00a0J, Hu\u00a0Y, Chen\u00a0Y, Zhou\u00a0Z, Shen\u00a0Y, Wang\u00a0Y, et\u00a0al. LNP-mRNA vaccine prevents type\u00a01 diabetes in non-obese diabetes mice. J\u00a0Control Release. 2024;375:513\u201323.","journal-title":"J Control Release"},{"key":"2627_CR59","volume-title":"Diabetes in America","author":"LM Jacobsen","year":"2024","unstructured":"Jacobsen\u00a0LM, Schatz\u00a0D, Herold\u00a0KC, Skyler\u00a0JS. Prevention of Type\u00a01 Diabetes. In: Lawrence\u00a0JM, Casagrande\u00a0SS, Herman\u00a0WH, Wexler\u00a0DJ, Cefalu\u00a0WT, Hrsg. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2024."},{"issue":"5","key":"2627_CR60","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00125-020-05376-1","volume":"64","author":"R Assfalg","year":"2021","unstructured":"Assfalg\u00a0R, Knoop\u00a0J, Hoffman\u00a0KL, Pfirrmann\u00a0M, Zapardiel-Gonzalo\u00a0JM, Hofelich\u00a0A, et\u00a0al. Oral insulin immunotherapy in children at risk for type\u00a01 diabetes in a\u00a0randomised controlled trial. Diabetologia. 2021;64(5):1079\u201392.","journal-title":"Diabetologia"},{"issue":"6","key":"2627_CR61","doi-asserted-by":"publisher","first-page":"e028578","DOI":"10.1136\/bmjopen-2018-028578","volume":"9","author":"AG Ziegler","year":"2019","unstructured":"Ziegler\u00a0AG, Achenbach\u00a0P, Berner\u00a0R, Casteels\u00a0K, Danne\u00a0T, Gundert\u00a0M, et\u00a0al. Oral insulin therapy for primary prevention of type\u00a01 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9(6):e28578.","journal-title":"BMJ Open"},{"issue":"7","key":"2627_CR62","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2337\/dc23-0036","volume":"46","author":"X Liu","year":"2023","unstructured":"Liu\u00a0X, Johnson\u00a0SB, Lynch\u00a0KF, Cordan\u00a0K, Pate\u00a0R, Butterworth\u00a0MD, et\u00a0al. Physical Activity and the Development of Islet Autoimmunity and Type\u00a01 Diabetes in 5\u2011 to 15-Year-Old Children Followed in the TEDDY Study. Diabetes Care. 2023;46(7):1409\u201316.","journal-title":"Diabetes Care"},{"issue":"9","key":"2627_CR63","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00125-015-3657-x","volume":"58","author":"MM Lamb","year":"2015","unstructured":"Lamb\u00a0MM, Frederiksen\u00a0B, Seifert\u00a0JA, Kroehl\u00a0M, Rewers\u00a0M, Norris\u00a0JM. Sugar intake is associated with progression from islet autoimmunity to type\u00a01 diabetes: the Diabetes Autoimmunity Study in the Young. Diabetologia. 2015;58(9):2027\u201334.","journal-title":"Diabetologia"},{"issue":"7","key":"2627_CR64","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold\u00a0KC, Bundy\u00a0BN, Long\u00a0SA, Bluestone\u00a0JA, DiMeglio\u00a0LA, Dufort\u00a0MJ, et\u00a0al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type\u00a01 Diabetes. N\u00a0Engl J Med. 2019;381(7):603\u201313.","journal-title":"N Engl J Med"},{"issue":"23","key":"2627_CR65","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos\u00a0EL, Dayan\u00a0CM, Chatenoud\u00a0L, Sumnik\u00a0Z, Simmons\u00a0KM, Szypowska\u00a0A, et\u00a0al. Teplizumab and beta-Cell Function in Newly Diagnosed Type\u00a01 Diabetes. N\u00a0Engl J Med. 2023;389(23):2151\u201361.","journal-title":"N Engl J Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02627-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:45Z","timestamp":1779315405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02627-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":65,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2627"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02627-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Roden hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Echosens, Madrigal, Merck, Novartis, Novo Nordisk, Sanofi, Target RWE. J.\u00a0Harreiter: hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Ultragenyx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}